Pamidronic acid

Generic Name: Pamidronic acid

Brand Names: Pamisol

Drug Type: Small Molecule

Chemical Formula: C_₃H_₁₁NO_₇P_₂

CAS Number: 40391-99-9

Unique Ingredient Identifier: OYY3447OMC

Background: Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming more popular.

Pamidronic acid was granted FDA approval on 31 October 1991.

Indication: Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.

Associated Conditions: Hypercalcemia of Malignancy, Osteolytic lesion, Paget’s Disease, Osteolytic Bone metastases

Clinical Trials

Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial

Phase 4

Completed

Conditions: Spondyloarthropathy

Interventions: Drug: Pamidronate
Drug: golimumab

First Posted Date: 2012-11-01

Last Posted Date: 2015-05-12

Lead Sponsor: Tuen Mun Hospital

Target Recruit Count: 30

Registration Number: NCT01718951

Locations: 🇭🇰
Tuen Mun Hospital, Hong Kong, Hong Kong

A Pilot Trial of IV Pamidronate for Low Back Pain

Phase 1

Completed

Conditions: Chronic Low Back Pain

Interventions: Drug: Pamidronate

First Posted Date: 2010-09-28

Last Posted Date: 2010-10-13

Lead Sponsor: Pappagallo, Marco, M.D.

Target Recruit Count: 44

Registration Number: NCT01210599

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States

A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.

Phase 4

Completed

Conditions: Bone Loss

Interventions: Drug: Pamidronate

First Posted Date: 2008-08-20

Last Posted Date: 2010-05-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 126

Registration Number: NCT00738257

Locations: 🇬🇧
Novartis Investigative Site, Frimley, United Kingdom

Efficacy of Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant

Phase 4

Completed

Conditions: Bone Disease, Metabolic

Interventions: Drug: Placebo
Drug: Disodium pamidronate

First Posted Date: 2008-04-14

Last Posted Date: 2008-04-14

Lead Sponsor: Hospital Clinic of Barcelona

Target Recruit Count: 79

Registration Number: NCT00657852

Locations: 🇪🇸
Hospital Clinic i Provincial of Barcelona, Barcelona, Spain

Prevention of Post Operative Bone Loss in Children

Not Applicable

Completed

Conditions: Osteoporosis
Spina Bifida
Cerebral Palsy
Osteogenesis Imperfecta
Osteopenia

Interventions: Other: saline
Drug: pamidronate

First Posted Date: 2008-04-10

Last Posted Date: 2023-08-22

Lead Sponsor: University of New Mexico

Target Recruit Count: 24

Registration Number: NCT00655681

Locations: 🇺🇸
University of New Mexico Carrie Tingley Hospital, Albuquerque, New Mexico, United States

Effect of Local Pamidronate in Preventing Bone Loss After Total Hip Arthroplasty

Phase 1

Not yet recruiting

Conditions: Mineral Density
Arthroplasty

First Posted Date: 2007-10-23

Last Posted Date: 2024-04-15

Lead Sponsor: General and Teaching Hospital Celje

Target Recruit Count: 40

Registration Number: NCT00548288

Locations: 🇸🇮
Department for Orthopaedic Surgery and Sports Trauma, Celje Teaching Hospital, Celje, Slovenia

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Pain

Interventions: Drug: Pamidronate
Drug: Zoledronic acid
Radiation: Sm 153 lexidronam

First Posted Date: 2007-06-05

Last Posted Date: 2018-08-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 39

Registration Number: NCT00482378

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Phase 3

Completed

Conditions: Multiple Myeloma

First Posted Date: 2006-09-15

Last Posted Date: 2007-01-04

Lead Sponsor: Nordic Myeloma Study Group

Target Recruit Count: 500

Registration Number: NCT00376883

Locations: 🇩🇰
Department of Haematology B, Aalborg Hospital, University of Aarhus, Aalborg, Denmark
🇩🇰
Department of Hematology L, Rigshospitalet, København Ø, Denmark
🇳🇴
Hematologisk seksjon, St.Olav Hospital, Trondheim, Norway

and more 11 locations